Oramed Pharmaceuticals financials
$4.69−1.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $13.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | 0.7% | — | — | — | — | — | — |
| Operating income | -$2.8M | -$3.7M | -$5.7M | -$2.4M | -$2.5M | -$4.5M | -$3.6M | -$3.1M | -$3.1M | -$3.0M | -$3.9M | -$2.9M |
| Net income | $78.2M | $38.3M | $9.2M | $48.4M | $13.3M | -$7.6M | -$10.2M | -$19.6M | $9.2M | $1.5M | $13.3M | -$3.2M |
| Net margin | — | — | — | — | — | −382.1% | — | — | — | — | — | — |
| Diluted EPS | $1.84 | $0.91 | $0.21 | $1.13 | $0.31 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.32 | $-0.08 |
| EBITDA | -$2.7M | -$3.6M | -$5.6M | -$2.4M | -$2.5M | -$4.5M | -$3.6M | -$3.0M | -$3.1M | -$2.9M | -$3.8M | -$2.8M |
| Operating cash flow | -$200.0K | -$2.9M | -$466.0K | -$1.6M | -$3.5M | -$3.5M | -$1.9M | -$7.1M | $2.1M | -$1.5M | -$1.4M | -$694.0K |
| Free cash flow | -$202.0K | -$2.9M | -$65.4M | -$1.6M | -$3.5M | -$3.5M | -$3.2M | -$7.1M | $2.1M | -$1.5M | -$1.4M | -$726.0K |
| Diluted shares | 42.5M | 42.0M | 43.1M | 42.8M | 42.6M | 41.2M | 39.3M | 40.9M | 41.6M | 41.6M | 41.6M | 40.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.2M | $13.2M | $45.9M | $52.2M | $15.8M | $74.5M |
| Short-term investments | $35.4M | $41.5M | $69.0M | $78.5M | $59.3M | $29.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $1.0K | $34.0K | $36.0K |
| Total assets | $369.6M | $268.8M | $230.9M | $220.5M | $161.7M | $147.5M |
| Total liabilities | $52.2M | $30.6M | $31.1M | $18.2M | $8.1M | $7.6M |
| Shareholders' equity | $317.5M | $238.3M | $199.7M | $202.3M | $153.6M | $139.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology